Company: APM
Filing Date: 2025-12-05
Form Type: 424B5
Source: 0001213900-25-118752
Chunk: 31

Company: Aptorum Group Ltd
Filing Date: 2025-12-05
Form: 424B5
Chunk 31
---
 to pay in cash to DiamiR, a fee in the amount equal to the higher of (i) 70% of cash
that Aptorum has as of the date of Termination, and (ii) $2,000,000 (the “Termination Fee”). In the event that the Merger
Agreement is terminated and that Aptorum has not raised capital by issuance of its equity securities during the Interim Period, each party
agrees to bear its own expenses incurred with the Merger and the related transactions.

Reasons for the Merger

Aptorum’s Reasons for the Merger

Since inception, the Company
has sought to maximize shareholder value by licensing and acquiring technologies that have scientific merit and ultimately, meaningful
market value after commercialization. We believe great opportunity exists for therapeutic agents developed for CNS indications, including
neurodegenerative diseases such as Alzheimer’s and Parkinson’s, as well as certain cancers like glioblastoma and neuroblastoma.
Due to the heterogeneity of these diseases, there is a wide spectrum of clinical manifestations and outcomes in patients with these conditions.
Therefore, there is a strong need for accurate, minimally invasive biomarkers reflective of pathophysiological processes underlying these
diseases that can be used for disease progression and treatment response monitoring. As such, the Company’s management finds great
value in DiamiR’s innovation and proprietary technology.

<div align='center'>10</div>

DiamiR’s platform technology, which is based on targeted selection and quantitative analysis of organ-enriched, including brain-enriched, microRNA (miRNAs) detectable in blood plasma, has a strong potential to provide molecular diagnostic solutions for risk assessment and monitoring of neuro and other indications in clinical trials, which we believe will enable more effective drug development for these indications. DiamiR’s CLIA/CAP-certified lab offers and is planning to offer additional genetic and protein markers used in clinical trials for. For example, DiamiR’s validated APOE genotyping test (APOE e4 allele is an established risk factor of AD, while APOE e2 is considered to be neuroprotective) can be used as a screening tool for enrollment into clinical trials targeting APOE e4 carriers or non-carriers. The Company is aware of a need in such test first-hand as it holds a position in a private life sciences company Alzheon that is developing a therapeutic agent for AD patients who are APOE e4 carriers.